14 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 14 of 14 clinical reviews.
A complete caregiver guide to administering Ozempic (semaglutide) injections in adolescents aged 12 to 17, covering dose escalation, injection technique, storage, missed doses, and safety monitoring.
A guide to transitioning adolescents on Ozempic (semaglutide) from pediatric to adult diabetes or obesity care, covering timing, dosing continuity, insurance, and monitoring protocols.
A guide covering how Ozempic (semaglutide 0.5 to 2.0 mg) affects adolescents aged 12 to 17 at school, in sports, and during daily activities, including dosing, side-effect management, and practical accommodations.
Step-by-step caregiver guidance for administering Ozempic (semaglutide) to adults 65 and older, including injection technique, hypoglycemia risk, dose titration, and storage tips backed by FDA labeling and geriatric clinical evidence.
A guide to semaglutide (Ozempic) use in geriatric patients aged 65+, covering dose adjustments, safety monitoring, transitional care handoffs, and evidence from SUSTAIN and SELECT trials.
A guide to semaglutide (Ozempic 0.5 to 2.0 mg) use in adults 65 and older, covering safe physical activity, cognitive engagement, fall risk, muscle preservation, and practical dose management.
A deep dive into how semaglutide (Ozempic) affects growth, puberty, bone density, neurodevelopment, and long-term health in adolescents ages 12 to 17, with trial data, dosing guidance, and monitoring protocols.
A guide to off-label semaglutide (Ozempic) use in adolescents ages 12 to 17, covering evidence, approved alternatives, dosing considerations, risks, and clinical decision-making.
A detailed clinical guide to semaglutide 0.5 to 2.0 mg (Ozempic) use in geriatric patients aged 65+, covering off-label indications, age-specific risks, dose titration, and evidence from major trials.
A guide to semaglutide (Ozempic 0.5 to 2.0 mg) use in adults aged 65 and older, covering efficacy, safety, muscle and bone considerations, cognitive effects, and prescribing guidance from major trials and guidelines.
A guide to semaglutide (Ozempic) use in children younger than 12, covering developmental safety signals, regulatory status, trial data, and evidence-based alternatives.
A guide covering how semaglutide (Ozempic) use in children under 12 affects school attendance, physical activity, nutrition, and daily routines, with evidence-based safety guidance.
Ozempic (semaglutide) is not FDA-approved for children under 12. This evidence-based guide explains the clinical field, transition planning considerations, and what to expect when a pediatric patient moves into adult GLP-1 care.
Ozempic (semaglutide 0.5 to 2.0 mg) is not FDA-approved for children under 12. This clinical review covers the current evidence, guideline positions, risks, and the rare circumstances where a pediatric endocrinologist might consider off-label use.